• NSCLC neoadjuvant setting 1
• lung cancer : small cell (SCLC)

 

• immune chekpoint inhibitors
• anti-CTLA-4
• ipilimumab based treatment
• ipilimumab plus SoC
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus SoC
• durvalumab based treatment
• durvalumab plus etoposide and platin
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab
• durvalumab plus tremelimumab plus SoC
• nivolumab plus ipilimumab

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs etoposide plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs non active control
• vs no additional treatment
• vs placebo

  All patients Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (liver )

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

lung cancer : small cell (SCLC), nivolumab alone vs. all, meta-analysis of study results

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;